ABOVE: © ISTOCK.COM,
VLADIMIR MANDIC
The first COVID-19 vaccine candidate was administered during a clinical trial in March 2020, a triumph shared worldwide by all those working to overcome the deadly virus. A year later, there are almost 100 vaccines being tested in human trials, including new approaches to immunization whose development has been accelerated by the pandemic. Researchers are now working not just to prevent COVID-19 infections, but to prevent reinfection and address emerging variants as well.
Below, The Scientist rounds up those vaccine candidates that have advanced to clinical trials.
Editor’s note: The introduction of this story was updated on April 15, 2021.
DEVELOPER(S)
VACCINE METHOD
EVIDENCE
STATUS
Finlay Vaccine Institute/Pasteur Institute
Cuba, Iran
A conjugate vaccine composed of the receptor-binding domain of the SARS-CoV-2 spike protein connected chemically to a modified tetanus protein
The vaccine is known as Soberana-02 or FINLAY-FR-2.
A second Phase 3 trial is ...
